

Preoperative lymph node staging for non-small cell lung cancer.**ESTS guidelines**

P. De Leyn, D. Lardinois, P. Van Schil, R. Rami-Porta, B. Passlick, M. Zielinski, D. Waller, T. Lerut, W. Weder

Abstract

Accurate preoperative staging and restaging of mediastinal lymph nodes in patients with non-small cell lung cancer (NSCLC) is of paramount importance. It will guide choices of treatment and determine prognosis and outcome. Over the last years, different techniques have become available. They vary in accuracy and procedure-related morbidity. The Council of the ESTS initiated a workshop on preoperative mediastinal lymph node (LN) staging. This resulted in guidelines for primary staging and restaging.

For primary staging, mediastinoscopy remains the gold standard for the superior mediastinal LNs. Invasive procedures can be omitted in patients with peripheral tumors and negative mediastinal positron emission tomography (PET) images. However, in case of central tumors, PET hilar N1 disease, low fluorodeoxyglucose uptake of the primary tumor and large LNs on CT (≥ 16 mm), invasive staging remains indicated. PET positive mediastinal findings should always be cyto-histologically confirmed. Transbronchial needle aspiration (TBNA), ultrasound-guided bronchoscopy with fine-needle aspiration (EBUS-FNA) and endoscopic esophageal ultrasound-guided fine needle aspiration (EEUS-FNA) are new techniques that provide cyto-histological diagnosis and are minimally invasive. Their specificity is high but the negative predictive value is low. Because of this, if they yield negative results, an invasive surgical technique is indicated. However, if fine needle aspiration is positive, this result may be valid as proof for N2 or N3 disease.

For restaging, invasive techniques providing cyto-histological information are advisable despite the encouraging results supported with the use of PET/CT imaging. Both endoscopic techniques and surgical procedures are available. If they yield a positive result, non surgical treatment is indicated in most patients.

Introduction

Correct staging of patients with non-small cell lung cancer (NSCLC) provides accurate information on the extent of disease and guides the choice of treatment. It is also fundamental for estimating prognosis and for comparison of studies. When there are no distant metastases, mediastinal lymph node (LN) involvement is the most important prognostic factor in patients with NSCLC and influences therapeutic strategies. It has been shown that patients with tumours in clinical stage III are a heterogeneous group in whom the extent of LN involvement before and after induction therapy determines outcome (multimodal versus single nodal, extracapsular invasion, nodal downstaging : Andre 2000, Ichinose 2001, Sawabata 2003)

Patients with preoperatively diagnosed involved mediastinal LN's have a dismal outcome when treated with surgery or radiotherapy alone. In order to improve the outcome in these patients, the concept of multimodality treatment has been introduced. In the subgroup of patients with IIIA-N2 disease induction chemotherapy, combined with either surgery and/or radiotherapy has proved to be effective (Rossel 1994, Roth 1994, Betticher, Lorent, Detterbeck, Intergroup trial, EORTC trial). Table 1.

Table 1 : Influence of downstaging of mediastinal lymph nodes after induction treatment and surgical resection for mediastinoscopy proven N2 disease

					Results in surgery group			
Author	Year	No of patients	%surgery	%complete resection	% downstaging\$	Survival Overall	Survival downstaging	Survival pN2
Bueno	2000	NR*	NR (103)	NR	28%	18%	36%	9%
Betticher	2003	90	87%	55%	63%	NR	61% (3y)	11%(3y)
Lorent	2004	131	57%	53%	45%	35%	44%	14%
Intergroup trial 0139	2005	202	81%	71%	41%	27%	41%	24%
EORTC 08941 trial	2005	167	92%	50%†	42%	16%	29%	7%

- *: Denominator is not in manuscript. Only data on complete resections after induction chemotherapy
- \$: downstaging : disappearance of tumor from mediastinal nodes
- % complete resection : number of complete resection on total number of included patients
- † strict criteria were used for complete resection (highest mediastinal lymph node had to be negative)
- NR : not reported
- Study by Betticher and Lorent give results of induction chemotherapy for N2 disease
- Intergroup trial compares CT/RT versus CT/RT + Surgery for patients with N2 disease
- EORTC trial compares RT versus Surgery in responding patients after induction chemotherapy for N2 disease.

Even in the setting of surgical combined modality, complete resection is an essential element in the potential of cure (Detterbeck, 2001). Therefore, an important aim of staging procedures in these patients will be to guide the multidisciplinary decision on whether the patient is a candidate for resection, based on baseline and postinduction assessment. If complete resection is considered unlikely, a non-surgical multimodality approach is preferred. Therefore, a precise and accurate preoperative and postinduction LN evaluation is mandatory.

After a first successful workshop on intra-operative LN staging (Lardinois, in Press), the ESTS Council initiated a second workshop on preoperative mediastinal LN staging.

The working group had 3 sessions in Zürich. Initial findings were presented and discussed at the postgraduate meeting of the EACTS-ESTS meeting in Barcelona (September 2005). The final paper was put on the website for discussion by all ESTS members. Their remarks were discussed and included in the final manuscript.

It is evident that both in primary staging and restaging, not every technique is available in every center. Therefore, staging and restaging techniques can differ between different countries and centers.

Primary mediastinal LN staging.

Imaging techniques

Chest CT-scan

Computer tomography (CT) still plays a central role in lung cancer imaging. For the N-factor, modern contrast CT is very accurate in detecting LN enlargement, but the clinical relevance of LN enlargement for staging is poor because small nodes may contain metastases in up to 20% (ref De Leyn, Eur J Cardiothorac Surg 97; Wu, Ann Thorac Surg 2001; Lardinois, Ann Thorac Surg 2003) and large nodes may be benign (e.g. in case of post obstructive pneumonia). A diameter larger than 1cm in the short axis is generally considered as the standard criterion for a suspicious LN. This definition reduces the false negative interpretations, which is of importance regarding the possible inclusion in an induction protocol. In a review, pooled data yielded a sensitivity of 57%, a specificity of 82%, a positive predictive value of 56% and a negative predictive value (NPV) of 83%, with a marked heterogeneity across individual studies [Table 2](Toloza 2003).

Table 2

Performance of different locoregional staging techniques (adapted from Toloza 2003)

	<u>Sensitivity (%)</u>	<u>Specificity (%)</u>	<u>NPV (%)</u>	<u>PPV (%)</u>	<u>Prevalence (%)</u>
CT	57	82	83	56	28
PET	84	89	93	79	32
Blind TBNA	76	96	71	100	70
EEUS-FNA	88	91	77	98	69
Mediastinoscopy	81	100	91	100	37

NPV: negative predictive value; PPV: positive predictive value; TBNA: transbronchial needle aspiration; EEUS-FNA: endoscopic esophageal ultrasound guided fine needle aspiration; Prevalence: proportion of patients with metastatic mediastinal nodes in the study cohorts.

This performance is insufficient for clinical decision making, and in many instances it is inappropriate to rely solely on CT scan for N-staging, but it can be of help in selecting the most appropriate procedure for tissue sampling of suspected LNs. In a best evidence topic,

cervical mediastinoscopy is recommended in patients with resectable NSCLC and small LN's on CT scan except from those with a T1 tumor with small LN's on CT scan. (Ghosh, 2006)

PET scan and PET-CT

Non-invasive lung cancer staging was substantially improved by the use of positron emission tomography with 18F-fluoro-2-deoxy-D- glucose (FDG-PET). A large number of accuracy studies and already 6 meta-analyses (Dwanema 1999; Fisher 2001; Hellwig 2001; Toloza 2003; Gould 2003; Birim 2005) have demonstrated that PET is superior to CT for mediastinal LN staging in potentially operable NSCLC.

Sensitivities and negative predictive values (NPVs) were comparable for PET compared with mediastinoscopy (table 2). However, the positive predictive value and the specificity of FDG PET-scan are lower than those of mediastinoscopy due to the fact that FDG is also taken up by inflammatory processes.

Due to the high NPV of PET-scan, invasive staging procedures like mediastinoscopy can generally be omitted in patients with clinical stage I NSCLC with negative mediastinal PET images. This implementation should be dealt with caution in case of patients with central tumors, central hilar N1-disease on CT scan, bronchio-alveolar cell carcinoma or in all situations with low FDG-uptake in the primary (Vansteenkiste 1997, Gupta 2001, Verhagen 2004) and large mediastinal PET-negative LNs (≥ 16 mm) on CT scan. In a recent meta-analysis (de Langen, 2006), a post-test probability for N2 disease of 21% was found in patients with PET negative nodes ≥ 16 mm.

We realize that some occasional patients with a false negative mediastinal PET will proceed straight to thoracotomy. When PET scan is implemented as discussed above, the rate of unforeseen N2 disease is expected to be below 10% (Verhaghen, Serra 2006). In these cases however, minimal N2 is usually found and a reasonable prognosis can be expected after surgical resection (Goldstraw 1994; De Leyn 1997).

However, the positive predictive value of PET scan is only 79%. In case of positive mediastinal PET, tissue confirmation is still needed to confirm LN metastasis before induction treatment can be started.

The actual resolution of PET scan is about 5-6 mm. The main drawback of PET is the poor quality of its anatomic information. Tracing focal abnormalities to specific LNs can be difficult or even impossible with use of PET alone, specially in the exact localization of a single focal abnormality between level 4R (N2) and level 10R (N1). Recently, integrated PET-CT scanners have been introduced. The great advantage of this technique consists of the

precise anatomical correlation of the radionuclide uptake, an identical positioning of the patient, no time interval for data acquisition and no additional work for collecting data. The first available studies show an increased diagnostic accuracy of integrated PET-CT with respect to nodal staging in comparison to all other standard imaging methods (Lardinois 2003).

Invasive techniques

Invasive surgical staging

Mediastinoscopy

Mediastinoscopy remains the gold standard for invasive staging of patients with potentially operable lung cancer. Different forms of mediastinoscopy have been described. Cervical mediastinoscopy is the most commonly used. It is a surgical open biopsy technique under general anesthesia (Carlens 1959, De Leyn, 2004).

According to the LN map proposed by Mountain and Dresler (figure 1), the following LN stations can be evaluated by cervical mediastinoscopy : the highest mediastinal LN station (level 1), the right and left superior paratracheal LN stations (level 2 right, level 2 left), the right and left inferior paratracheal LN stations (level 4 right, level 4 left), and the subcarinal LN station (level 7)




Figure 1 : Mountain Dresler map

There is no internationally accepted recommendation on how many LN stations should be examined at cervical mediastinoscopy. There are no data indicating that more systematic sampling at mediastinoscopy makes a difference, but extrapolation from data on occasional and systematic sampling at thoracotomy suggests that this may be important (Izbicki 1995). The opinions vary among working groups and authors around the world:

- the American Thoracic Society (ATS, 1980) stated that all reachable nodal stations should be explored. According to the ATS nodal map, these include the right and left superior paratracheal stations (levels 2R and 2L), right and left inferior paratracheal (levels 4R and 4L), right and left tracheobronchial (levels 10R and 10L), and subcarinal (level 7) stations. The ATS also recommended performing left parasternal mediastinotomy to explore the subaortic (level 5) and anterior mediastinal (level 6) stations in patients with left lung tumors.
- Ginsberg (1991) recommended the exploration of the superior and inferior paratracheal stations on the ipsilateral side and of the tracheobronchial stations bilaterally, along with the subcarinal station.
- for Detterbeck (2001), the ideal exploration would include at least one node from the right and left, superior and inferior paratracheal, and subcarinal stations, unless more nodes are present.
- Smulders et al (2005) assessed the quality of mediastinoscopies performed both in teaching and non-teaching hospitals. They found a large variability in the performance of mediastinoscopy for initial staging for NSCLC. In only 40% of mediastinoscopies performed for NSCLC three or more LN levels were sampled (Smulders 2005). They suggest that the minimally acceptable exploration includes biopsy of nodes from the inferior paratracheal stations on both sides, and from the subcarinal station, with the addition of at least one contralateral LN. They consider that the inclusion of the superior paratracheal nodes on both sides could not be required in standard clinical practice, because they might be difficult to reach.

In summary, there seem to be two standards for mediastinoscopy described according to the latest LN map (Mountain-Dresler 1997):

- Ideally, the following nodal stations should be explored and their LNs biopsied:
 - right and left superior paratracheal nodes (level 2R and level 2L)
 - right and left inferior paratracheal nodes (level 4R and level 4L)
 - subcarinal (level 7)

- But a lesser standard could be accepted for routine clinical practice:
 - right and left inferior paratracheal nodes (level 4R and level 4L)
 - subcarinal nodes (level 7)

The ESTS working group recommends to systematically explore and biopsy always the right and left lower paratracheal nodes and the subcarinal nodes. Additionally, if present, the upper paratracheal LNs should be sampled and biopsied .

An advantage of mediastinoscopy over fine needle aspiration is that a more complete mediastinal mapping can be performed including contralateral LN stations. This might be important in the differentiation and treatment planning of patients with single and multi-level N2 disease. In a recent review, the sensitivity of cervical mediastinoscopy varied between 72% and 89%, with an average of 81% with a NPV of 91% (Tolozza 2003). The prevalence of N2 disease in these series was 37% which is the expected prevalence of N2 disease in patients with potentially resectable NSCLC. The results of the suboptimal sensitivity can partly be explained by the fact that some LN stations (levels 5, 6, posterior part of level 7 and levels 8 and 9) are not accessible by cervical mediastinoscopy.

More recently, mediastinoscopy is performed by the use of a videomediastinoscope (De Leyn 2000, 2004, figure 2). This definitely improves visualization of the operative field and may lead to a higher accuracy in staging and a better standardisation of the technique (Moureau 2001, Lardinois 2003). In a recent paper, the learning curve of video-assisted mediastinoscopy was short compared to conventional mediastinoscopy (Martin-Ukar 2004).




Figure 2 : Cervical videomediastinoscopy

Recently, some groups have developed techniques for mediastinal lymphadenectomy through a cervicotomy approach (VAMLA, video-assisted mediastinoscopic lymphadenectomy [Hürtgen 2002; Leschber 2004], TEMLA, transcervical extended mediastinal lymphadenectomy [Kuzdzal 2005]). The aim of both techniques is to perform a complete bilateral lymphadenectomy of the mediastinum including stations 2,4,7 and 8 (VAMLA) and stations 1,2,3A, 3P, 4,5,6,7 and 8 (TEMLA) for staging purposes. The potential advantage of these two lymphadenectomy techniques is that by removing the nodes, the false negative results caused by micrometastases can be reduced. The results of these two studies with a


limited number of patients show a very high accuracy and NPV (between 0.95 and 1). However the value of these techniques needs to be further explored before they can be implemented in routine practise.

Tumors of the left upper lobe may metastasize to the subaortic (level 5) and anterior mediastinal (level 6) nodes. These nodal stations can not be reached by cervical mediastinoscopy. *Left parasternal mediastinotomy* (Mc Neill, Chamberlain 1966, Olak 1996), *extended cervical mediastinoscopy* (Ginsberg 1987), and left *thoracoscopy* allow exploration and biopsy of these nodal stations and should be used in combination with cervical mediastinoscopy to stage these LN stations as indicated. Thoracoscopy can also be used for LN levels which are not accessible by routine mediastinoscopy (level 8, level 9) (Pass, 2005). These lymph node levels can be biopsied with esophageal ultrasound-guided fine needle aspiration (EEUS/FNA).

Invasive-non surgical staging

Endoscopic techniques are minimally invasive approaches that provide histological or cytological confirmation of nodal tumor involvement. **Transbronchial needle aspiration (TBNA)** has been shown to be safe and useful in patients with enlarged mediastinal LNs. However, this technique has a moderate yield, is a “blind” technique, operator dependent, and the results depend on the size of the LN. In a recent overview, a sensitivity of 76% and a false negative rate of 29% were reported for conventional TBNA in clinical N2 disease (Detterbeck invasive staging, 2003, Toloza, Table 2). This high false negative rate compromises the use of conventional TBNA for routine mediastinal LN staging, however it can be used as a preliminary diagnostic test complemented in negative cases with surgical staging. The accuracy can be improved by guidance with endoscopic ultrasonography (**EBUS-TBNA**). Additionally, the hilar (station 10) and intrapulmonary nodal stations can be biopsied with TBNA. EBUS-TBNA and cervical mediastinoscopy can provide histology of the superior mediastinal LNs (Level 2 and 4, right and left) and the subcarinal LNs (level 7) (figure 3).

Cervical mediastinoscopy
EBUS-TBNA



EUS-FNA




Figure 3 : illustration of which nodal levels can be reached by cervical mediastinoscopy and EBUS-TBNA (Fig 3A) versus nodal levels which are accessible by EEUS-FNA (Fig 3B)

In a recent meta-analysis including 13 studies in which all TBNA results were confirmed by surgical biopsies, it was shown that the sensitivity of TBNA critically depends on the prevalence of mediastinal LN metastases. In populations with a lower prevalence of mediastinal metastases, the sensitivity of TBNA is much lower than reported in recent lung cancer guidelines (Holty, 2005).

Esophageal ultrasound-guided fine needle aspiration (EEUS- FNA) is mainly suitable for the assessment of LNs in the posterior part of levels 4L, 5 and 7, and in the inferior mediastinum at levels 8 and 9 as described on the Mountain-Dresler map (figure 4).

A review of the literature reported a pooled sensitivity of 88%, a specificity of 91%, a positive predictive value of 98% and a NPV of 77%. A recent study in 100 patients with potentially operable NSCLC who were scheduled for mediastinoscopy showed that the combination of mediastinoscopy and EEUS-FNA significantly improved sensitivity and NPV (Annema, 2005).


We should however notice that these studies were performed in patients with a high suspicion of N2-N3 disease (Kramer, Ann Thorac Surg 2003).

When the prevalence of involved mediastinal LNs is high as mentioned above, an improved sensitivity is to be expected which does not reflect the accuracy in patients with normal sized LNs. It is generally accepted that endoscopic techniques (both EBUS and EEUS/FNA) are suitable to provide histological proof of suspicious mediastinal LNs but can not be used to exclude mediastinal LN disease because of the low NPV.

Transthoracic needle aspiration (TTNA) is performed with CT or, less often, with fluoroscopic guidance. Generally, TTNA is used in patients with enlarged or bulky mediastinal LNs. Almost all mediastinal nodal stations are accessible with this technique; stations 1,2,4,5 and 6 are accessible using anterior parasternal approach and stations 4,7,8 and 9 are approached with the posterior paraspinal approach. (Akamatsu H Ann Thorac Surg 1996;62.:352-5, Zwischenberger J, Chest 2002, .Toloza Chest 2003)

Guidelines for baseline mediastinal LN staging

- Chest CT is still the basic imaging modality in lung cancer. However, CT scan of the chest is not accurate enough for mediastinal LN staging. When only CT scan is available, invasive staging is advised in every patient except for a T1 tumor or a small peripheral T2 tumor in the outer third of the lung with no or small LNs on CT scan.
- Invasive staging can be omitted in patients with stage I NSCLC and negative mediastinal PET images. However, in case of central tumors, PET hilar N1 disease, low FDG uptake of the primary tumor and large LNs on CT (≥ 16 mm), invasive staging remains indicated.
- PET positive mediastinal findings should be histologically or cytologically confirmed .
- Transbronchial needle aspiration (TBNA), ultrasound-guided bronchoscopy (EBUS-FNA), esophagoscopy (EEUS-FNA) and transthoracic needle aspiration (TTNA) are new techniques that provide cyto-histological diagnosis and are minimally invasive techniques. They can be complementary to surgical invasive staging techniques. Their specificity is high, but their NPV is low. For this reason an invasive surgical technique is indicated if they yield negative results. However, if fine needle aspiration is positive, this result may be valid as proof of N2 or N3 disease.
- Cervical mediastinoscopy provides the advantage that a more complete mapping of mediastinal LNs can be performed. Ideally, all accessible lymph node stations (2R, 4R, 2L 4L and 7) should be explored and biopsied. At least one ipsilateral, one contralateral and the subcarinal LNs should be biopsied.
- The proposed algorithm for primary mediastinal staging is detailed in figure 4.



- a : In central tumors, tumors with large LNs (= 1,6 cm) and/or PET N1 disease invasive staging remains indicated
 b : if no PET is available, mediastinoscopy is indicated except for T1N0 and periheral (outer third of lung)T2N0 tumors
 c : Endoscopic techniques are minimally invasive and can be the first choice
 d : Due to its higher NPV mediastinoscopy remains indicated

EEUS : endoscopic esophageal ultrasound
 EBUS : endobronchial ultrasound
 NPV : negative predictive value

Figure 4 : The proposed algorithm to follow for primary mediastinal staging

Mediastinal lymph node restaging after induction therapy.

Recent studies suggest that mainly patients with initial stage IIIA or IIIB and mediastinal downstaging will benefit from surgical resection (Table 1). However, post-operative morbidity and mortality may be higher after resection following induction therapy compared with resection without induction treatment (Martin J, J Clin Oncol 2002).

As a consequence, mediastinal restaging after induction therapy is required to aid proper selection of patients likely to benefit from surgical resection.

An important question remains whether a better local control and survival are obtained by induction therapy and surgery compared to standard chemoradiotherapy. Recently, the results of two large randomized trials became available. In the intergroup 0139 trial patients with proven stage IIIA-N2 NSCLC were randomized between a full course of chemoradiotherapy and induction chemoradiotherapy + surgery (Albain 2005, Rusch 2005). There was no significant difference in overall survival between both arms. However, there was a difference in progression-free survival favoring the surgical arm, and patients downstaged to ypN0 disease had a far better prognosis. The rate of locoregional recurrence was also significantly less in the surgical arm.

In the EORTC 08941 phase III trial patients with proven clinical stage IIIA-N2 disease were randomized between surgery and radiotherapy after a response to induction chemotherapy (Van Meerbeeck 2005, Van Schil 2005). There was no difference in overall and progression-free survival between both arms. The data of these two trials are however only available in abstract form which impairs a precise analysis and a fair interpretation of the results

The mediastinum can be principally restaged by the same techniques as applied in primary staging.

Imaging techniques

In primary staging, **CT-scan** has proved to have a low accuracy. It is not surprising that the accuracy of CT-scan in restaging the mediastinum is also low. In two studies, the sensitivity of CT scan for mediastinal restaging was 41% and 59%, specificity 75% and 62%, and accuracy 58% and 60%, respectively (Mateu-Navarro 2000, De Leyn 2006)

For mediastinal restaging after induction chemotherapy, **PET-scan** is more accurate than CT but is clearly not as accurate as in untreated patients. In most studies (Akhurst 2002, Ryu

2002, Cerfolio 2003, Port 2004, Hellwig 2004), the sensitivity is reported to be 50%-60% with a good specificity of 85%-90%. So, in a high proportion of patients, PET-scan is false negative regarding mediastinal nodal involvement after induction therapy. The reason for this poor sensitivity is not clear. A very small mass of residual tumor, such as posttreatment microscopic foci surrounded by fibrosis may be more difficult to detect. Changes in the microenvironment of the tumor such as altered perfusion due to postchemotherapy changes, may also impair presentation of FDG to the metastatic LNs.

In a prospective study (De Leyn) the use of PET-CT fusion images significantly increased the accuracy through better localisation of focal FDG uptake in mediastinal LNs or other vascular-mediastinal structures. This study showed that PET-CT had a high positive predictive value (93%) in detecting residual mediastinal disease. Moreover, complete resectability was low (57%) in patients with persistent mediastinal findings on PET-CT. However, in another study (Cerfolio 2006) the PPV was only 75% and the authors concluded that persistent positive mediastinal findings on PET should be histopathological proven.

It seems that the comparison of SUV max values before and after induction chemotherapy allow prediction of histopathologic response in the primary tumor and mediastinal LNs and have prognostic value (Pöttgen 2006, Cerfolio 2006).

Invasive techniques

Invasive surgical staging

Repeat mediastinoscopy, although technically more difficult than the first procedure, offers the advantage of providing histological evidence of response after induction therapy.

Only a few centers have reported their experience with repeat mediastinoscopy (table 3). Mateu-Navarro et al reported on 42 patients who underwent re-mediastinoscopy after induction chemotherapy for mediastinoscopy proven N2 disease. The sensitivity to detect residual mediastinal disease was 70%. These data were confirmed in an update (Rami Porta, 2003). Van Schil et al reported very similar results in 32 patients with no mortality and only minimal morbidity (Van Schil, 2002-2003). The largest experience of repeat mediastinoscopies after induction therapy to date was recently reported by Stamatis (Stamatis 2005). In a study from the Netherlands, re-mediastinoscopy was performed in 15 patients. Re-mediastinoscopy was inadequate or incomplete in 6 patients and the authors concluded that the examination was not that effective (Pitz).

A prospective study evaluated the accuracy of re-mediastinoscopy and PET-CT in restaging the mediastinum after video-mediastinoscopy proven N2 disease in 30 patients (De Leyn, 2006). The authors concluded that, after a thoroughly performed initial videomediastinoscopy, repeat videomediastinoscopy was technically feasible but inaccurate due to severe adhesions and fibrosis. The sensitivity to detect residual positive mediastinal LNs was only 29%, with an accuracy of 60%. It seems that the degree of adhesions and mediastinal fibrosis is mainly secondary to preinduction mediastinoscopy rather than to induction treatment itself. In a study comparing accuracy and safety of video-mediastinoscopy in patients without pre-treatment and in patients after induction therapy but without preinduction mediastinoscopy, sensitivity, specificity, and accuracy were comparable without additional morbidity (Lardinois, *Ann Thorac Surg* 2003).

A study investigated the role of **VATS** in restaging of the mediastinum after induction therapy for N2 disease in 70 patients (Jaklitsch, 2005). In 17 patients the VATS procedure was not successful due to fibrosis. A sensitivity of 75%, a specificity of 100% and a NPV of 75,8% were reported. However, the value of this technique needs to be further explored before it can be implemented in routine practise.

Invasive non-surgical techniques

An alternative, less invasive test to restage the mediastinum after induction chemotherapy is **transbronchial or transesophageal ultrasound guided biopsy**. A study from the Netherlands reported results in 19 patients with proven N2 disease which were restaged by EEUS after induction chemotherapy (Annema, 2003). Diagnostic accuracy in this study was 83%.

Conclusions

Restaging of the mediastinum after induction treatment for N2 disease is of paramount importance. CT is by far not accurate enough for restaging. Re-mediastinoscopy has proven to be feasible but due to adhesions and fibrosis, the intervention is technically challenging and sensitivity and accuracy are much lower than after a first mediastinoscopy. The accuracy of PET in mediastinal restaging is far from optimal, mainly due to its low sensitivity. Fusion images with PET-CT is reported to improve the results. Less invasive techniques, such as EEUS-FNA seem to yield similar results as VATS and re-mediastinoscopy. An alternative

approach is the use of EBUS or EEUS-FNA for primary staging and reserve mediastinoscopy for mediastinal restaging after induction therapy.

In order to obtain the most precise restaging, an integration of these procedures is highly recommended, especially in the context of clinical trials and to maintain the morbidity as low as possible.

Guidelines for restaging

Restaging of the mediastinum after induction therapy is necessary.

At the present time, neither CT, PET or PET-CT are accurate enough to make final further therapeutic decisions based on their results.

An invasive technique providing cyto-histological information is recommended. For restaging, endoscopic techniques or surgical invasive techniques can be used. If they yield a positive result, non-surgical treatment seems to be indicated in most of the patients. The choice may be dependent on the availability of the technique and expertise of the center.

References (not yet uniform style)

Akamatsu H, Terashima M, Koike T, Takizawa T, Kurita Y: Staging of primary lung cancer by computed tomography –guided percutaneous needle cytology of mediastinal lymph nodes. *Ann Thorac Surg* 1996;62:352-5.

Akhurst T, Downey RJ, Ginsberg MS et al : An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. *Ann Thorac Surg* 73:259-266, 2002

Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) versus CT/RT followed by surgical resection for stage IIIA-N2 non-small cell lung cancer: outcomes update of North American Intergroup 0139 (RTOG 9309). *J Clin Oncol* 2005; 23 no.16S:624s (abstract 7014)

American Thoracic Society. Clinical staging of primary lung cancer. *Am Rev Respir Dis* 1983; 127: 659-64.

Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. *J Clin Oncol* 2000; 18: 2981-9.

Annema JT, Versteegh MI, Veselic M, Voigt P, Rabe KF. Endoscopic ultrasound fine-needle aspiration in the diagnosis and staging of lung cancer and its impact on surgical staging. *JCO* 2005;23:8357-61

Annema JT, Veselic M, Versteegh MIM, Willems LNA, Rabe KF. Mediastinal restaging : EUS-FNA offers a new perspective. *Lung Cancer* 2003;42:311-318

Betticher DC, Hsu Schmitz SF, Totsch M et al : Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small cell lung cancer: a multicenter phase II trial. *J Clin Oncol* 21:1752-1759, 2003

Birim O, Kappetein AP, Stijnen T et al : Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in non-small cell lung cancer. *Ann Thorac Surg* 79:375-382, 2005

Bueno R, Richards WG, Swanson SJ et al : Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. *Ann Thorac Surg* 70:1826-1831, 2001

Carlens E. Mediastinoscopy : a method for inspection and tissue biopsy in the superior mediastinum. *Dis Chest* 36:343-352, 1959

Cerfolio RJ, Ojha B, Mukherjee S et al : Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. *J Thorac Cardiovasc Surg* 125:938-944, 2003

Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy : a prospective study. *J Thorac Cardiovasc Surg* 2006; 131:1229-1235

De Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS. The size of mediastinal lymph nodes and its relation with metastatic involvement : a meta-analysis. *Eur J Cardiothorac Surg* 2006;29:26-29

De Leyn P, Vansteenkiste J, Cuypers P, et al. Role of cervical mediastinoscopy in staging of non-small cell lung cancer without enlarged mediastinal lymph nodes on CT scan. *Eur J Cardiothorac Surg* 1997; 12: 706-12.

De Leyn P, Lerut T : Videomediastinoscopy, in Yim AP, Hazelrigg SR, Izzat MB, Landreneau RJ, Mack MJ, Naunheim KS (ed): *Minimal access in cardiothoracic surgery*. WB Saunders , 2000, pp 169-174.

De Leyn P, Lerut T : Videomediastinoscopy. *Multimedia Manual of Cardiothoracic Surgery*. 10.1510/mmcts.2004.000166; 2004.

De Leyn P, Schoonooghe P, Deneffe G, Van Raemdonck D, Coosemans W, Vansteenkiste J, Lerut T. Surgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease)

De Leyn P, Stoobants S, Dewever W, Lerut T, Coosemans W, Decker G, Nafteux P, Van Raemdonck D, Mortelmans L, Nackaerts K, Vansteenkiste J. Prospective comparative study of integrated PET-CT with remediastinoscopy in the assessment of residual mediastinal disease after induction chemotherapy for mediastinoscopy proven stage IIIa-N2 non-small cell lung cancer. *JCO*, 2006, 24:3333-3339

Detterbeck FC, Jones DR, Parker Jr LA. Intrathoracic staging. In: Detterbeck FC, Rivera MP, Socinski MA, Roseman JG (Editors). *Diagnosis and treatment of lung cancer. An evidence-based guide for the practicing clinician*. WB Saunders Company, Philadelphia, 2001; 73-93.

Detterbeck FC, Socinski MA. Induction therapy and surgery for I-IIIa,B non-small cell lung cancer, in : Detterbeck FC, Socinski MA, Rivera MC, Rosenman JG (ed). *Diagnosis and treatment of lung cancer. An evidence-based guide for the practising clinician*. Philadelphia, W.B. Saunders Company, 2001, pp267-82

Dwamena BA, Sonnad SS, Angobaldo JO, et al : Metastases from non-small cell lung cancer: mediastinal staging in the 1990s. Meta-analytic comparison of PET and CT. *Radiology* 213:530-536, 1999

Fischer BM, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. *Lancet Oncol* 2:659-666, 2001

Ghosh S, Nanjiah P, Dunning J. Should all patients with non-small cell lung cancer who are surgical candidates have cervical mediastinoscopy preoperatively? *Interactive cardiovascular and thoracic surgery* doi:10.1510/ICVTS.2005.122838

Ginsberg RJ, Rice TW, Goldberg M et al. Extended cervical mediastinoscopy: a single staging procedure for bronchogenic carcinoma of the left upper lobe. *J Thorac Cardiovasc Surg* 1987; 94: 673-8.

Ginsberg RJ. Standard cervical and extended mediastinotomy. In: Shields TW (Editor). Mediastinal surgery. Lea & Febiger, Philadelphia, 1991; 77-80.

Goldstraw P, Mannam GC, Kaplan DK, Michail P. Surgical management of non-small cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg 1994;107:19-28

Gould MK, Kuschner WG, Rydzak CE, et al : Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small cell lung cancer: a meta-analysis. Ann Intern Med 139:879-892, 2003

Gupta NC, Rogers JS, Graeber GM, Gregory JL, Waheed U, Mullet D, Atkins M. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 2002, 122, 1918-1924.

Hellwig D, Graeter TP, Ukena D, et al : Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 128:892-899, 2004

Hellwig D, Ukena D, Paulsen F, et al : Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000 (in German). Pneumologie 55:367-377, 2001

Holty JEC, Kuschner WG, Gould MK. Accuracy of transbronchial needle aspiration for mediastinal staging of non-small cell lung cancer : a meta-analysis. Thorax 2005;60:949-955

Hürtgen M, Friedel G, Tomes H, Fritz P. Radical video-assisted mediastinoscopic lymphadenectomy (VAMLA)- technique and first results. Eur J Cardio-thorac Surg 2002; 21: 348-51.

Ichinose Y, Kato H, Koike T, et al. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg 2001; 122: 803-8.

Izbicki JR, Passlick B, Karg O, Bloechle C, Pantel K, Knoefel WT, Thetter O. Impact of radical systematic mediastinal lymphadenectomy on tumour staging in lung cancer. *Ann Thorac Surg* 1995;59:209-14

Jaklitsch MT. Prospective phase II trial of pre-resection thoracoscopic (VATS) restaging following neoadjuvant therapy for IIIA-N2 NSCLC : results of CALGB 39803. *J Clin Oncol* 2005; 23 (16S) : 636s (abstract 7065)

Kramer H, Groen HJM. Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer. *Ann Thorac Surg* 2003; 238: 180-8.

Kuzdzal J, Zielinski M, Papla B, et al. Transcervical extended mediastinal lymphadenectomy – the new operative technique and early results in lung cancer staging. *Eur J Cardiothorac Surg* 2005; 27: 384-90.

Lardinois D, Schallberger A, Betticher D, Ris HB. Postinduction video-mediastinoscopy is as accurate and safe as video-mediastinoscopy in patients without pretreatment for potentially operable non-small cell lung cancer. *Ann Thorac Surg* 2003, 75, 1102-1106.

Lardinois D, Weder W, Hany TF, et al : Staging of non-small cell lung cancer with integrated positron-emission tomography and computed tomography. *N Engl J Med* 348:2500-2507, 2003

Lardinois D, De Leyn P, Van Schil PE, Rami Porta R, Waller , Passlick B, Zielinski M, Junker K, Rendina E, Ris HB, Hasse J, Detterbeck F, Lerut , Weder W. ESTS guidelines for intraoperative lymph node staging in non-small-cell lung cancer. *Eur J Cardiothorac Surg*, in press

Leschber G, Holinka G, Linder A. Video-assisted mediastinoscopic lymphadenectomy (VAMLA) – a method for systematic mediastinal lymphnode dissection. *Eur J Cardiothorac Surg* 24:192-195, 2003

Lorent N, De Leyn P, Lievens Y, et al : Long-term survival of surgically staged IIIA-N2 non-small cell lung cancer treated with surgical combined modality approach: analysis of a 7-year experience. *Ann Oncol* 15: 1645-1653, 2004

Martin J, Ginsberg RJ, Venkatraman ES. Long-term results of combined-modality therapy in resectable non-small cell lung cancer. *J Clin Oncol* 2002; 15: 1989-95.

Martin-Ucar AE, Chetty GK, Vaughan R, Waller DA. A prospective audit evaluating the role of video-assisted cervical mediastinoscopy (VAM) as a training tool. *Eur J Cardiothorac Surg* 2004, 26, 393-395.

Mateu-Navarro M, Rami-Porta R, Bastus-Piulats R, et al : Remediastinoscopy after induction chemotherapy in non-small cell lung cancer. *Ann Thorac Surg* 2000, 70;391-395, 2000

Mc Neill TM, Chamberlain JM. Diagnostic anterior mediastinotomy. *Ann Thorac Surg* 1966; 2:532-539.

Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. *Chest* 1997, 111:1718-1723, 1997

Mouroux J, Venissac N, Alifano M. Combined video-assisted mediastinoscopy and video-assisted thoracoscopy in the management of lung cancer. *Ann Thorac Surg* 2001, 72, 1698-1704.

Olak J. Parasternal mediastinotomy (Chamberlain procedure). *Chest Surg Clin North America* 1996; 6: 31-40.

Pass HI. Mediastinal staging 200 : Pictures, copes and scalpels. *Sem oncol* 2005;32:269-278

Pitz CCM, Maas KW, Van Swieten HA, et al : Surgery as part of combined modality treatment in stage IIIB non-small cell lung cancer. *Ann Thorac Surg* 74:164-9, 2002

Port JL, Kent MS, Korst RJ, et al : Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. *Ann Thorac Surg* 2004;77:254-9

Rami-Porta R, Mateu-Navarro M, Serra-Mitjans M, Hernandez-Rodriguez H. Mediastinoscopy: comments and updated results. *Lung Cancer* 2003; 42: 363-4.

Rosell R, Gomez Codina J, Camps C, et al : A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. *N Engl J Med* 330:153-158, 1994

Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G, Gauler T, Antoch G, Bockisch A, Stuschke M. Value of 18F-Fluoro-2-Deoxy-D-Glucose-Positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. *Clin Cancer Res* 2006; 12: 97-106.

Roth JA, Fossella F, Komaki R, et al : A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung Cancer. *J Natl Cancer Inst* 86:673-680, 1994

Rusch V, Albain K, Turrisi A, et al. Phase III trial of concurrent chemotherapy and radiotherapy (CT/RT) versus CT/RT followed by surgical resection for stage IIIA-N2 non-small cell lung cancer: outcomes and implications for surgical management in North American Intergroup 0139 (RTOG 9309). *Lung Cancer* 2005; 49 (suppl.2):S15 (abstract O-035).

Ryu JS, Choi NC, Fischman AJ, et al : FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. *Lung Cancer* 35:179-187, 2002

Sawabata N, Keller SM, Matsumura A, Kawashima O, Hirono T, Osaka Y, Maeda H, Fukai S, Kawahara M, The Japan National Chest Hospital Study Group for Lung Cancer. The

impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer. *Lung Cancer* 2003;42:69-77

Serra M, Cirera L, Rami-Porta R, Basts R, Gonzalez S, Simo M, Domenech M, Barbeta E, Sloer JM, Belda J. Routine positron emission tomography (PET) and selective mediastinoscopy is as good as routine mediastinoscopy to rule out N2 disease in non-small cell lung cancer. Abstract No 7031, JCO 2006 Annual Meeting Proceedings 371s

Smulders SA, Smeenk FWJM, Janssen-Heijnen MLG, et al : Surgical mediastinal staging in daily practice. *Lung Cancer* 47:243-251, 2005

Stamatis G, Fechner S, Hillejan L, et al. Repeat mediastinoscopy as a restaging procedure. *Pneumologie* 2005; 59:862-866.

Tolozza EM, Harpole L, Detterbeck F. Invasive staging of non-small cell lung cancer: A review of the current evidence. *Chest* 2003;123:157S-166S.

Tolozza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: A review of the current evidence. *Chest* 2003;123:137S-146S.

Van Meerbeeck J, Kramer G, Van Schil P, et al. A randomized trial of radical surgery versus thoracic radiotherapy in patients with stage IIIA-N2 non-small cell lung cancer after response to induction chemotherapy (EORTC 08941). *J Clin Oncol* 2005; 23 no.16S:1095s (abstract 7015)

Van Schil P, Van Der Schoot J, Poniewierski J, et al : Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer. *Lung Cancer* 37:281-285, 2002

Van Schil P. The restaging issue. *Lung Cancer* 2003;42:S39-S45

Van Schil P, Van Meerbeeck J, Kramer G, et al. Morbidity and mortality in the surgery arm of EORTC 08941 trial. *Eur Resp J* 2005; 26:192-197.

Vansteenkiste JF, Stroobants SG, De Leyn PR, et al : Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer : A prospective analysis of 50 cases. *Chest* 1997, 112:1480-1486.

Venissac N, Alifano M, Mouroux J. Video-assisted mediastinoscopy : experience from 240 consecutive cases. *Ann Thorac Surg* 76:208-12, 2003

Verhagen AT, Bootsma GP, Tjan-Heijnen VCG, van der Wilt GJ, Cox AL, Brouwer MHJ, Corstens FHM, Oyen WJG. FDG-PET in staging lung cancer. How does it change the algorithm? *Lung cancer* 2004;44:175-81

Wu J, Ohta Y, Minato H, Tsunozuka Y, et al. Nodal occult metastasis in patients with peripheral lung adenocarcinoma of 2.0 cm or less in diameter. *Ann Thorac Surg* 2001; 71: 1772-8.

Yasufuku K, Chiyo M, Sekine Y, et al. Real-time endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. *Chest* 2004; 126: 122-8.

Zwischenberger J, Savage C, Alpard S, Anderson C, Marroquin S, Goodacre B: Mediastinal transthoracic needle and core lymph node biopsy. Should it replace mediastinoscopy?. *Chest* 2002;121:1165-70.